The facility will support full vaccine and therapeutic manufacturing for diseases prevalent in Africa. The Cape Town facility is funded by the Gates Foundation, the European Union, and the German government.
Biovac said the lab will allow it to produce vaccines from early development through final formulation using advanced technologies such as messenger RNA (mRNA). It is also expected to make other treatments while fostering innovation and developing homegrown intellectual property.
Advancing African Vaccine Self-Sufficiency
The laboratory includes infrastructure for developing, screening, evaluating, and producing mRNA drug substances. It also houses a specialized suite for nanoparticle formulation, which encapsulates and protects mRNA, as well as dedicated spaces for bacterial and cell culture, cell bank storage, and handling sensitive biological materials.
“The establishment of our new product development laboratory is a major milestone for Biovac and for African vaccines and vaccine innovation. It gives us the capability to develop and test next-generation vaccines using the most advanced technology available, ensuring that Africa is not left behind in responding to current and future vaccine-preventable diseases,” said Biovac CEO Morena Makhoana.
Mark Suzman, CEO of the Gates Foundation, said the lab “brings the promise of faster, more reliable access to lifesaving vaccines – developed and produced in Africa, for Africa.”
Aligning with Continental Goals
The project supports the African Union’s plan to raise Africa’s share of locally produced vaccines from 1% to 60% by 2040 to strengthen health security. The AU aims to reach that target with support from member states, donors, multilateral lenders, and private-sector initiatives like Biovac’s.
Biovac, 47.5% owned by two South African government agencies, supplies vaccines for the country’s childhood immunization program. It was founded to distribute imported vaccines for the Department of Health before gradually building capacity for final-stage manufacturing, or “fill and finish.”
The company provides vaccines in South Africa for tuberculosis, tetanus, diphtheria, polio, Haemophilus influenzae, and hepatitis B. During the COVID-19 pandemic, Biovac partnered with Pfizer and BioNTech to produce vaccines for the African Union.
Walid Kéfi
MTN Zambia tests Starlink satellite service connecting phones directly from space Direct-to...
Togo parliament adopts WAEMU law against currency counterfeiting Bill defines offences including ...
Since its 2019 IPO, Airtel Africa paid Deloitte over $37 million in audit and non-audit fees,...
Tilenga oil project required land from 4,954 households in Uganda Over 99% of affected households...
World Bank announces $137 million to boost West Africa digital economy Program expands broad...
African startups raised more than $272 million in February 2026, according to Africa: The Big Deal. Funding increased 56% from January, signaling...
Starsight Energy Africa has secured $15 million in mezzanine financing from British International Investment. The funds will support the...
Algeria is preparing a new licensing round, Algeria Bid Round 2026, for oil and gas exploration blocks. The tender will be organized by ALNAFT, the...
KCB Group plans to acquire a stake in an Ethiopian bank as part of its expansion strategy. The investment depends on regulatory approval in Ethiopia’s...
Mbanza Kongo, located in northern Angola, is one of the most important historic cities in Central Africa. The capital of Zaire Province, it stands on a...
Actress Wunmi Mosakuand director Kaouther Ben Haniarepresent Africa among contenders at the 2026 Oscars. Mosaku received a nomination for Best...